-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the global pandemic of the new coronavirus , the development of an effective COVID-19 vaccine is currently the most important research focus in the world.
COVID-19
Compared with other traditional methods, such as those involving inactivated or live virus vaccines or recombinant proteins, the preventive vaccine platform based on messenger RNA is a recently developed vaccine technology.
prevention
The candidate vaccine BNT162b1 is one of two lipid nanoparticle (LNP) formulations, pharmacological optimization, and 1-methylpseudourea nucleoside modified mRNA (modRNA) vaccines.
BNT162b1 encodes the SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and is one of several messenger RNA-based vaccine candidates in clinical trials.
Recently, researchers assessed the progress of a single-center (Jiangsu Province, China), parallel-group, preliminary safety a double-blind trials of candidate vaccines BNT162b1, tolerability and immune immunogenicity data, the test 144 In a healthy SARS-CoV-2 negative Chinese participant.
These participants were immunized to randomly receive 10 micrograms or 30 micrograms of BNT162b1 or a placebo base and booster vaccination at a 1:1:1 ratio at an interval of 21 days.
Compared with placebo, BNT162b1 induced 50% of virus neutralizing antibody titer and specific RBD binding and S1 binding antibody response
Compared with placebo, BNT162b1 induced 50% of virus neutralizing antibody titer and specific RBD binding and S1 binding antibody responseThe results show that local reactions and systemic events are usually dose-related, transient, and mild to moderate.
Fever is the only grade 3 adverse event Fever is the only grade 3 adverse event
BNT162b1 induced a powerful interferon-γ T cell response to peptide libraries including RBD in young and older Chinese adults, and the geometric mean neutralization titer reached 2.
Induced the response of powerful interferon-γ T cells to peptide libraries including RBD Induced the response of powerful interferon-γ T cells to peptide libraries including RBD
In summary, the results of this test show that BNT162b1 has acceptable safety and produces high levels of humoral and T cell responses in Asian populations.
BNT162b1 has acceptable safety BNT162b1 has acceptable safety
Original source:
Original source:Jingxin Li et al.
Jingxin Li et al.
Leave a message here
